Research and Markets: Prostate Cancer Global Clinical Trials Review - Q4 2010

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/72f6ab/prostate_cancer_gl) has announced the addition of GlobalData's new report "Prostate Cancer Global Clinical Trials Review, Q4, 2010" to their offering.

Our clinical trial report, Prostate Cancer Global Clinical Trials Review, Q4, 2010" provides data on the Prostate Cancer clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout the world, focusing on the status of participation by the developing nations. It offers coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides information pertaining to the number of trials for the key drugs for treating Prostate Cancer.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope:

  • Data on the number of clinical trials conducted in North America, South And Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status and trial success rate
  • Review of key discontinued trials (suspended, withdrawn and terminated)
  • Overview of the enrollment pattern by phase for the past decade
  • Number of clinical trials segmented by key drugs
  • Clinical trial overview of top 20 companies, which include Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, and so on.
  • Clinical trial overview of top 20 Universities / Institutes / Hospitals including National Cancer Institute, Cancer Research UK, Cancer Research Institute , and others

Reasons to buy:

  • Understand the dynamics of a particular indication as a whole
  • Examine the performance of the trials in terms of their status, recruitment, success rates and others
  • Obtain discontinued trial information for trials across the globe
  • Understand the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Key Topics Covered:

  • Introduction
  • Prostate Cancer
  • Report Guidance
  • Clinical Trials by Region
  • Clinical Trials by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by BRIC Nations
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Unaccomplished Trials of Prostate Cancer
  • Subjects Recruited Over a Period of Time
  • Prominent Sponsors
  • Top Companies Participating in Prostate Cancer Therapeutics Clinical Trials
  • Prominent Drug Comparison

Clinical Trial Profiles on 39 Companies, Some Include:

  • AstraZeneca PLC
  • Ferring Pharmaceuticals
  • Novartis AG
  • Sanofi-Aventis
  • Abbott Laboratories
  • Amgen Inc.
  • Cougar Biotechnology, Inc. (Inactive)
  • Ferring Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Millenium: The Takeda Oncology Company
  • Bayer AG
  • Ipsen Limited
  • Alberta Health Services
  • National Cancer Institute (NCI)
  • Memorial Sloan Kettering Cancer Center
  • The University of Texas M. D. Anderson Cancer Center
  • University of Wisconsin Madison
  • Duke University
  • European Organization for Research and Treatment of Cancer
  • Barbara Ann Karmanos Cancer Institute
  • UCLA's Jonsson Comprehensive Cancer Center
  • Stanford University
  • Massachusetts General Hospital
  • University of Medicine and Dentistry New Jersey
  • Wake Forest University

To view all companies mentioned and for more information visit http://www.researchandmarkets.com/research/72f6ab/prostate_cancer_gl



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Clinical Trials  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.